IKAROS: a potential prognostic marker in pancreatic ductal adenocarcinoma

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter M. Cruz Ramos
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors M. Cruz Ramos1, M. Rodriguez-Remirez1, P. Minguez2, A. Cebrian1, L. del Puerto-Nevado1, A. Celdran3, J. Garcia-Foncillas Lopez1
  • 1Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM University Hospital "Fundación Jiménez Díaz", Madrid, Spain, /
  • 2Department of Genetics, Instituto de Investigacion Sanitaria-University Hospital Fundacion Jimenez Diaz (IIS - FJD, UAM), Madrid, Spain, /
  • 3Hepatobiliary and Pancreatic Surgery Unit, Department of Surgery, University Hospital "Fundación Jiménez Díaz", Madrid, Spain, /

Abstract

Pancreatic ductal adenocarcinoma (PADC) is one of the principal causes of cancer-related death worldwide. New therapeutic options against PADC had limited success. Anti-tumor immune response has been involved in tumor progression promotion. Effectors CD4+ and CD8+ T facilitate tumor cell degradation and, regulatory T cells (Tregs) maintain peripheral immune tolerance against self-antigens and foreign antigens. This critical balance between these immune cells are lost in PADC, Cd4+ and Treg percentages are elevated in PADC patients and are associated with a decrease of CD8+ cells. Increase of Treg and CD4+ cells had a negative impact in PADC survival. IKAROS is a member of zinc finger transcription factors family, encoded by gene IKZF1, is a critical key in lymphocyte differentiation. Preclinical studies suggest a relation between microenvironment and its proteasomal degradation, the loss of IKAROS may contribute to an imbalance in T cell percentages. The analysis of IKAROS mRNA expression in patients with PADC haveńt been reported previously, the present study evaluates its role in PADC patient's survival.